Management of benign prostatic hyperplasia by family physicians

Canadian Journal of Urology

Volumn 17, Issue , 2010, Pages 26-34

  Toguri, Allan ^a   Barkin, Jack ^b  

^a SCARBOROUGH HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

BPH; Flow rate; LUTS; PSA; Symptom complex; Symptom index

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN;

AGED; BLOOD; FOLLOW UP; GENERAL PRACTICE; GENERAL PRACTITIONER; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; MICTURITION DISORDER; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; REVIEW; RISK ASSESSMENT; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URINE RETENTION; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; COMBINED MODALITY THERAPY; FAMILY PRACTICE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHYSICIANS, FAMILY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; URINARY RETENTION; URINATION DISORDERS; URODYNAMICS;

EID: 77952468102     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Barkin J. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm. Can J Urol 2008;15(Supplement 1):21-30.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardization Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-178.
3. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296(19):2319-2328.
4. Djavan B, Waldert M, Ghawidel C, Marberger M. Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 2004;14(1):45-50.
5. Nickle JC, Herschorn S, Corcos J, Donnelly B, Drover D, Elhilali M, Goldenberg L, Grantmyre J, Laroche B, Norman R, Piercy B, Psooy K, Steinhoff G, Trachtenberg J, Saad F, Tanguay S: Canadian Prostate Health Council; Canadian Urological Association Guidelines Committee. Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urol 2005; 12(3):2677-2683.
6. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148(5):1549-1557;discussion 1564.
7. Abrams P, Cardozo L, Fall M, Griffi ths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61(1): 37-49.
8. Barry MJ, Williford WO, Fowler FJ Jr, Jones KM, Lepor H. Filling and voiding symptoms in the American Urological Association symptom index: the value of their distinction in a Veterans Affairs randomized trial of medical therapy in men with a clinical diagnosis of benigh prostatic hyperplasia. J Urol 2000;164(5):1559-1564.
9. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specifi c antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;5(3)3:581-589.
10. Kell JS. Prostate-specifi c antigen tests and prostate cancer screening: an update for primary care physicians. Can J Urol 2010;17(Suppl 1):18-25.
11. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008;15(3):193-199.
12. Kirby R, Lepor H, Campbell's Urology, 9th edition, Philadelphia, Pa: Saunders: 2007:2766-2802.
13. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alphaadrenoceptor antagonists. BJU Int 2005:95 (Suppl 4):29-36.
14. Djavan B, Marberger M. A meta-analysis on the effi cacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
15. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, fi nasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003:349(25):2387-2398
16. Kazuki K, Masaki Y, Yukio H for the Silodosin Clinical Study Group. Silodosin, a new alpha 1a-adrenoceptor selective antagonist for treating benign prostatic hyperplasia: resuls of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98(5):1019-1024.
17. Steers WD. 5alpha-reductase activity in the prostate. Urology 2001;58(6 Suppl 1):17-24:discussion 24.
18. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000;37(4):367-380.
19. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alphareductase inhibitor. J Clin Endocrinol Metab 2004;89(5):2179-2184.
20. McConnell J D, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of fi nasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Effi cacy and Safety Study Group. N Engl J Med 1998;338(9):557-563.
21. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Effi cacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-441.
22. Roerhborn CG, Siami P, Barkin J, Damiao R, Becher E, Minana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group. The infl uence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009;55(2):461-471.
23. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; on behalf of the CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4 year results from the CombAT study. Eur Urol 2010;57(1):123-131. Epub 2009 Sept 19.
24. Roehrborn CG, Siami P, Barkin J Damilao R, Major-Walker K, Morrill B, Montorsi F: CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179(2):616-621.
25. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003;44(4):461-466.
26. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with fi nasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001;58(2):203-209.
27. Nickel JC, Barkin J, Koch C, Dupont C, Elhilali M. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J 2008;2(1):16-21.
28. Andriole G et al. Late breaking news. Headline results from the REDUCE trial: the effect of dutasteride on prostate cancer risk reduction. AUA Annual Meeting 2009 Chicago, Illinois, USA.
29. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The infl uence of fi nasteride on the development of prostate cancer. New Engl J Med 2003;349(3):215-224.
30. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 2008;1:174-181.
31. Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. Curr Med Res Opin 2009; 25(11):2663-2669.